US 12,447,218 B1
Radioconjugates directed to MHC-complexed antigens in cancer
Dale L Ludwig, Rockaway, NJ (US)
Filed by Actinium Pharmaceuticals, Inc., New York, NY (US)
Filed on Feb. 9, 2022, as Appl. No. 17/668,134.
Claims priority of provisional application 63/147,700, filed on Feb. 9, 2021.
Int. Cl. C07K 16/28 (2006.01); A61K 51/10 (2006.01); C07K 14/725 (2006.01); A61K 38/00 (2006.01)
CPC A61K 51/1045 (2013.01) [C07K 14/7051 (2013.01); C07K 16/2809 (2013.01); C07K 16/2833 (2013.01); A61K 38/00 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2319/33 (2013.01)] 4 Claims
 
1. A method for treating a cancer in a human subject, comprising administering a composition consisting essentially of an effective amount of a radiolabeled antibody comprising:
an antibody component comprising the complementarity determining regions (CDRs):
 
 CDRH1 comprising amino acid sequence 
 
 (SEQ ID NO: 177)
 
 DYAMH, 
 
 
 
 CDRH2 comprising amino acid sequence 
 
 (SEQ ID NO: 178)
 
 GISWNSGSIGYADSVKG,
 
 
 
 CDRH3 comprising amino acid sequence 
 
 (SEQ ID NO: 179)
 
 GRGFHYYYYGMDI,
 
 
 
 CDRL1 comprising amino acid sequence 
 
 (SEQ ID NO: 180)
 
 GGNNIGSRSVH,
 
 
 
 CDRL2 comprising amino acid sequence 
 
 (SEQ ID NO: 181)
 
 DDSDRPS, and
 
 
 
 CDRL3 comprising amino acid sequence 
 
 (SEQ ID NO: 182)
 
 QVWDSRTDHWV;
a chelator chemically conjugated to the antibody component, wherein the chelator is DOTA or a DOTA derivative; and
225Ac radionuclide chelated by the chelator.